ADMA News and Press, ADMA Biologics Inc From 06/21/22

Ramsey, N.J. and Boca Raton, Fla., June 21, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived bi...

At 2022 Russell indexes annual reconstitution, following notable health care stocks will be added to and deleted from the Russell 3000 Index. Notable additions: Clover Health Investments (CLOV), Aurinia Pharmaceuticals (AUPH), Nano-X Imaging (NNOX), ADMA Biologics (ADMA),&...

I made a mistake, this was VRCA's third FDA rejection. VRCA has been pointing fingers instead of executing. VRCA press releases cross the line. Enough is enough! For further details see: I Would Avoid Verrica Pharmaceuticals Until CEO Change

ADMA reported a great quarter in all respects. Management gave great guidance for 2024-2025 which shows that ADMA is undervalued with an enterprise value of only $324M. ADMA's non-recurring expenses incurred this quarter relating to its strategic review give some indication about ...

ADMA Biologics, Inc. (ADMA) Q1 2022 Earnings Conference Call May 11, 2022 4:30 P.M. ET Company Participants Skyler Bloom - Senior Director, Business Development and Corporate Strategy Adam Grossman - President and Chief Executive Officer Brian Lenz - Executive Vice President, Chief Financial ...

ADMA Biologics (NASDAQ:ADMA) is up 4% in after-hours trading after stating it is boosting its 2022 revenue guidance in light of revenue growth in Q1 2022. In its Q1 results, the specialty plasma-derived biologics company said it expects full-year revenue of at least $130M, up from $...

ADMA Biologics press release (NASDAQ:ADMA): Q1 GAAP EPS of -$0.13 misses by $0.04. Revenue of $29.1M (+81.8% Y/Y) beats by $0.95M. Gross profit for the first quarter of 2022 was $3.7 million, compared to a gross loss of $1.7 million for the first quarter of 2021. Enabled by the strong start t...

First Quarter 2022 Total Revenues Were Approximately $29.1 Million, an 81% Increase Over First Quarter 2021 Increases Full Year 2022 Total Revenue Guidance to $130 Million or More From $125 Million Gross Margin Growth and Narrowing Net Losses Expected Throughout 2022 and...

RAMSEY, N.J. and BOCA RATON, Fla., May 04, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived bio...

Institutional ownership has grown in the past 6 months. An activist investor is watching ADMA intently. ADMA's Q4 report was very promising. For further details see: ADMA: Pertinent Updates